Home›Companies›Healthcare›TOBY

Toby, Inc.

Develops urine tests to detect cancer and other diseases early.

Updated Nov 17, 2026·Latest SEC filing Jul 15, 2025·Suggest an edit

About TOBY

TOBY is a private company based in Wilmington, Delaware, incorporated in 2023 in Delaware. It has reported $1,414,990 raised in two offerings on Form D since February 2025. Its chief executive is Matthew Laskowski.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
May 30, 2025Jul 15, 2025$814,990fully sold7$116KEquityRule 506(b)Form D ↗
Dec 16, 2024Feb 4, 2025$600,000fully sold4$150KEquityRule 506(b)Form D ↗
Total, two offerings$1,414,990

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on TOBY's Form D filed Jul 15, 2025.

DS
Dragan Sebisanovic
Executive officer and director
On every Form D that TOBY has filed: 2 filings, from Feb 4, 2025 to Jul 15, 2025.
MN
Mark November
Director
First appears on the Form D that TOBY filed on July 15, 2025; on 1 of its 2 filings.
Mark November appears on 2 Form D filings at 2 companies:
  • TOBY, director: Jul 15, 2025
  • EndoSure, director: Nov 19, 2026
ML
Matthew Laskowski
Founder & CEO, director
On every Form D that TOBY has filed: 2 filings, from Feb 4, 2025 to Jul 15, 2025.
JH
Joseph Hanssen
Director
First appears on the Form D that TOBY filed on July 15, 2025; on 1 of its 2 filings.
JL
John Legget
Director
First appears on the Form D that TOBY filed on July 15, 2025; on 1 of its 2 filings.

Sources

  1. SECToby, Inc. filing history
  2. PressTOBY appoints Dan Collins as advisor